Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Wilkinson

Urology Naples, FL Medical Doctor

NPI 1407905847 CMS profile 109611

1035 Piper Blvd Unit 1, Naples, FL 34110

Open in the dashboard

General payments

$215,570

646 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$66,547

7 holdings reported · through program year 2025

Through program year 2025, David Wilkinson of Naples, FL is reported in the CMS Open Payments database as having received $215,570 across 646 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $66,547 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,114 59
2024 General $5,790 77
2023 General $3,147 39
2022 General $11,535 39
2021 General $76,502 147
2020 General $71,954 133
2019 General $43,529 152
2024 Ownership $14,921 2
2023 Ownership $14,628 1
2022 Ownership $6,931 1
2021 Ownership $6,436 1
2020 Ownership $16,503 1
2019 Ownership $7,127 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Wilkinson
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Wilkinson were reported at $3,114. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Wilkinson Urology median Middle half National median
2019 $43,529 $480 $147–$1,201 $163
2020 $71,954 $246 $87–$645 $114
2021 $76,502 $358 $111–$1,000 $132
2022 $11,535 $476 $143–$1,263 $149
2023 $3,147 $560 $168–$1,461 $160
2024 $5,790 $563 $170–$1,464 $164
2025 $3,114 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. NeoTract Inc. $105,383 167 payments
  2. Teleflex LLC $101,283 244 payments
  3. Axonics Modulation Technologies, Inc. $2,878 25 payments
  4. Astellas Pharma US Inc $983 34 payments
  5. Boston Scientific Corporation $701 17 payments
  6. Coloplast Corp $553 13 payments
  7. Pfizer Inc. $294 14 payments
  8. Janssen Biotech, Inc. $286 13 payments
  9. Calyxo, Inc. $283 8 payments
  10. AbbVie, Inc. $256 6 payments
  11. Other $2,668 105 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $66,269 32 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $55,738 42 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $39,750 21 payments
  4. Travel and Lodging $28,985 97 payments
  5. Food and Beverage $20,424 446 payments
  6. Honoraria $4,000 1 payment
  7. Education $405 7 payments
Products named General payments · program years 2019–2025
  1. UROLIFT Interventional Urology $119,091 273 payments
  2. UroLift System Interventional Urology $75,268 104 payments
  3. UroLift System Interventional Urology $10,606 24 payments
  4. Axonics $2,651 21 payments
  5. Bulkamid $2,207 9 payments
  6. BARRIGEL $1,259 6 payments
  7. XTANDI $896 36 payments
  8. UROLIFT Interventional Urology $773 2 payments
  9. MYRBETRIQ $401 23 payments
  10. Axonics r-SNM System $396 10 payments
  11. Other $4,648 181 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Urology: 1,053

Drug cost

$23

Median for Urology: $101,464

Branded share of claims

0%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ezetimibe Generic 11 $23

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$55,085

Medicare's payments for the services billed

Medicare patients

169

Average age 77

Services billed

543

34 women, 135 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 51%
Diabetes 28%
Cancer 28%
Chronic kidney disease 27%
Atrial fibrillation 22%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
POSLUMA
$55 — —
ADSTILADRIN
$47 — —
BOTOX
$32 — —
ERLEADA
$26 — —
PLUVICTO
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

646 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record